Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hadi Askarifirouzjaei, Leila Khajoueinejad, Amir Salek Farrokhi, Mohammad-Taher Tahoori, Mehdi Fazeli, Taki Tiraihi & Ali Akbar Pourfathollah. (2019) Implications of immunotherapy with high-dose glatiramer acetate in acute phase of spinal cord injury in rats. Immunopharmacology and Immunotoxicology 41:1, pages 150-162.
Read now
Read now
Aaron L Boster, Corey C Ford, Orit Neudorfer & Yossi Gilgun-Sherki. (2015) Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 15:6, pages 575-586.
Read now
Read now
Articles from other publishers (20)
Dnyandev G. Gadhave, Vrashabh V. Sugandhi & Chandrakant R. Kokare. (2024) Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis. Brain Research 1822, pages 148674.
Crossref
Crossref
Danina Krajišnik, Jela Milić & Snežana Savić. (2019) Challenges of in vitro characterization of nonbiological complex drugs: Example of parenteral preparations with liposomal drug carriers. Arhiv za farmaciju 69:4, pages 176-198.
Crossref
Crossref
Stefanie Kuerten, Leila J. Jackson, Joel Kaye & Timothy L. Vollmer. (2018) Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. CNS Drugs 32:11, pages 1039-1051.
Crossref
Crossref
Jody Corey-Bloom, Alaina M. Aikin, Ashley M. Gutierrez, Jwan S. Nadhem, Taylor L. Howell & Elizabeth A. Thomas. (2017) Beneficial effects of glatiramer acetate in Huntington’s disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Research 1673, pages 102-110.
Crossref
Crossref
M. von Euler Chelpin & T. Vorup-Jensen. (2017) Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments. Scandinavian Journal of Immunology 85:5, pages 321-330.
Crossref
Crossref
Iris Grossman, Volker Knappertz, Daphna Laifenfeld, Colin Ross, Ben Zeskind, Sarah Kolitz, David Ladkani, Liat Hayardeny, Pippa Loupe, Ralph Laufer & Michael Hayden. (2017) Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Progress in Neurobiology 152, pages 114-130.
Crossref
Crossref
Patricia K. Coyle. (2017) Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives. Multiple Sclerosis International 2017, pages 1-10.
Crossref
Crossref
R.M. Valenzuela, M. Kaufman, K.E. Balashov, K. Ito, S. Buyske & S. Dhib-Jalbut. (2016) Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis. Journal of Neuroimmunology 300, pages 59-65.
Crossref
Crossref
Vegard Nygaard, Einar Andreas Rødland & Eivind Hovig. (2016) Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses. Biostatistics 17:1, pages 29-39.
Crossref
Crossref
Tal Hasson, Sarah Kolitz, Fadi Towfic, Daphna Laifenfeld, Shlomo Bakshi, Olga Beriozkin, Maya Shacham-Abramson, Bracha Timan, Kevin D. Fowler, Tal Birnberg, Attila Konya, Arthur Komlosh, David Ladkani, Michael R. Hayden, Benjamin Zeskind & Iris Grossman. (2016) Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology 290, pages 84-95.
Crossref
Crossref
Josephine S. D’Alessandro, Jay Duffner, Joel Pradines, Ishan Capila, Kevin Garofalo, Ganesh Kaundinya, Benjamin M. Greenberg, Daniel Kantor & Tanmoy C. Ganguly. (2015) Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®. PLOS ONE 10:10, pages e0140299.
Crossref
Crossref
G. Ya. Shvarts & G. V. Ramenskaya. (2015) Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs. Pharmaceutical Chemistry Journal 49:4, pages 213-219.
Crossref
Crossref
Sarah Kolitz, Tal Hasson, Fadi Towfic, Jason M. Funt, Shlomo Bakshi, Kevin D. Fowler, Daphna Laifenfeld, Augusto Grinspan, Maxim N. Artyomov, Tal Birnberg, Rivka Schwartz, Arthur Komlosh, Liat Hayardeny, David Ladkani, Michael R. Hayden, Benjamin Zeskind & Iris Grossman. (2015) Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports 5:1.
Crossref
Crossref
Zhong-Xiang Xie, Hong-Liang Zhang, Xiu-Juan Wu, Jie Zhu, Di-Hui Ma & Tao Jin. (2015) Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis. Mediators of Inflammation 2015, pages 1-20.
Crossref
Crossref
Vera Weinstein, Rivka Schwartz, Iris Grossman, Benjamin Zeskind & J. Michael Nicholas. 2015. Non-Biological Complex Drugs. Non-Biological Complex Drugs
107
148
.
S.E. Kolitz, F. Towfic, I. Grossman, M.R. Hayden & B. Zeskind. (2014) Use of genetic technologies to compare medicines. Clinical Genetics 86:5, pages 441-446.
Crossref
Crossref
Fadi Towfic, Jason M. Funt, Kevin D. Fowler, Shlomo Bakshi, Eran Blaugrund, Maxim N. Artyomov, Michael R. Hayden, David Ladkani, Rivka Schwartz & Benjamin Zeskind. (2014) Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic. PLoS ONE 9:1, pages e83757.
Crossref
Crossref
Jill Conner. (2014) Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis. Journal of Autoimmunity and Cell Responses 1:1, pages 3.
Crossref
Crossref
Huub Schellekens, Sven Stegemann, Vera Weinstein, Jon S. B. de Vlieger, Beat Flühmann, Stefan Mühlebach, Rogério Gaspar, Vinod P. Shah & Daan J. A. Crommelin. (2013) How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider. The AAPS Journal 16:1, pages 15-21.
Crossref
Crossref
Lesley J. Scott. (2013) Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis. CNS Drugs 27:11, pages 971-988.
Crossref
Crossref